CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $10.01M fell 80.3% year over year, behind the -76.1% change in trailing-twelve-month gross profit. Sequentially, it rose 1409.4% from the prior quarter. Over 3 fiscal years it compounded at +12.8% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -80.3% toward the trailing-twelve-month pace of -76.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.01M+1409.4% QoQ
Last fiscal yearDec 2025
$76.2M-44.8% YoY
LTMMar 2026
$35.29M-76.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.3%——
1 year-44.8%——
3-year CAGR+12.8%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
76.2M USD
Year-over-year change
-44.8%
4-year CAGR
+19.5%

Gross Profit vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 gross profit of $35.29M is the 7th highest of the 10 companies compared; the peer median is $71.82M.
  • Its year-over-year change of -76.1% is the lowest of 8, against a peer median of +35.8%.
  • Gross profit amounts to 99.3% of revenue for CTMX, versus a peer median of 86.5%.
CTMX Competitors Peer median
Gross Profit for CTMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M +545.5%—86.5%
ZYMEZymeworks Inc.LTM Sep 2026$182.57M +35.8%-36.4%68.6%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M +16.2%-9.3%69.9%
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M +52.1%+17.0%98.7%
ADCTADC Therapeutics S.A.LTM Mar 2026$71.82M +2.1%-29.1%90.7%
XNCRXencor, Inc.LTM Jun 2026$45.46M -54.8%—43.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$35.29M -76.1%+12.8%99.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026$13.83M ——99.8%
ADAGAdagene Inc.LTM Jun 2024-$118.77K —-6.2%14.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$742K +99.6%—662.5%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CTMX) $71.82M+35.8%-9.3%86.5%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.31M53.16M101.21M138.1M76.2M
Cost of Revenue00000
Gross Profit37.31M53.16M101.21M138.1M76.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development114.19M111.65M77.68M83.38M68.73M
Selling, General & Admin39.16M42.85M30.02M29.73M29.84M
Operating Expenses153.35M154.5M107.7M113.11M98.57M
Depreciation & Amortization2.71M2.44M2.18M1.77M1.38M
EBITDA(113.16M)(96.87M)5.5M33.86M(15.75M)
EBITDA Margin-303.3%-182.2%5.4%24.5%-20.7%
Operating Income(116.04M)(101.34M)(6.48M)25M(22.36M)
Operating Margin-311.0%-190.6%-6.4%18.1%-29.3%
Interest Income255K1.68M9.84M7.14M5.21M
Interest Expense00000
Other Income / Expenses172K2.02M9.81M7.1M5.23M
Income Before Tax(115.87M)(99.32M)3.32M32.09M(17.13M)
Pre-Tax Margin-310.5%-186.8%3.3%23.2%-22.5%
Income Tax Expense003.89M224K238K
Net Income(115.87M)(99.32M)(569K)31.87M(17.37M)
Net Margin-310.5%-186.8%-0.6%23.1%-22.8%
EPS (Basic)(1.26)(1.48)(0.01)0.38(0.15)
EPS (Diluted)(1.26)(1.48)(0.01)0.38(0.15)
Weighted Avg Shares64.15M65.74M73.81M84.44M137.94M
Weighted Avg Shares (Diluted)64.15M65.74M73.81M84.75M137.94M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.